Credit Suisse’s Harvard Bioscience HBIO Stock Holding History

Credit Suisse’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,310	Closed	-$97K	–	3209
2023 Q1	$97K	Hold	2,310	–	–	﹤0.01%	3208
2022 Q4	$64K	Buy	+2,310	New	+$56.9K	﹤0.01%	3384
2022 Q3	–	Sell	-2	Closed	–	–	4132
2022 Q2	$0	Buy	+2	New	+$90	﹤0.01%	4083
2021 Q1	–	Sell	-1,091	Closed	-$47K	–	4411
2020 Q4	$47K	Buy	+1,091	New	+$40.7K	﹤0.01%	4259
2016 Q3	–	Sell	-6,064	Closed	-$173K	–	4154
2016 Q2	$173K	Buy	+6,064	New	+$193K	﹤0.01%	3917
2016 Q1	–	Sell	-1,047	Closed	-$37K	–	4102
2015 Q4	$37K	Buy	1,047 +9	+0.9%	+$308	﹤0.01%	4150
2015 Q3	$39K	Sell	1,038 -30	-3%	-$1.4K	﹤0.01%	4193
2015 Q2	$61K	Sell	1,068 -4,295	-80%	-$244K	﹤0.01%	4443
2015 Q1	$312K	Buy	5,363 +2,566	+92%	+$138K	﹤0.01%	3840
2014 Q4	$159K	Buy	+2,797	New	+$133K	﹤0.01%	4339
2014 Q3	–	Sell	-5,712	Closed	-$260K	–	4519
2014 Q2	$260K	Buy	5,712 +1,436	+34%	+$60.3K	﹤0.01%	4198
2014 Q1	$203K	Buy	4,276 +913	+27%	+$41.6K	﹤0.01%	4347
2013 Q4	$158K	Buy	3,363 +157	+5%	+$6.86K	﹤0.01%	4389
2013 Q3	$127K	Buy	3,206 +805	+34%	+$31.7K	﹤0.01%	4078
2013 Q2	$86K	Buy	+2,401	New	+$91.9K	﹤0.01%	4046

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Credit Suisse's HBIO Position: Q2 2023 in Review

Credit Suisse sold out of Harvard Bioscience (HBIO) in Q2 2023, closing a stake of 2,310 shares — an estimated $97K sold.

Credit Suisse first reported a position in HBIO in Q2 2013 and held it in 15 quarters. The position peaked at $312K in Q1 2015. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2023.

Credit Suisse reported no remaining Harvard Bioscience position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 2,310 Harvard Bioscience shares in Q2 2023, an estimated $97K.
Credit Suisse first reported a position in Harvard Bioscience in Q2 2013 and held it in 15 quarters.
Credit Suisse's Harvard Bioscience position peaked at $312K in Q1 2015.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.